U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H14N4O2S
Molecular Weight 350.394
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PF-915275

SMILES

NC1=CC=CC(NS(=O)(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)C#N)=N1

InChI

InChIKey=ZESFDAKNYJQYKO-UHFFFAOYSA-N
InChI=1S/C18H14N4O2S/c19-12-13-4-6-14(7-5-13)15-8-10-16(11-9-15)25(23,24)22-18-3-1-2-17(20)21-18/h1-11H,(H3,20,21,22)

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800025590 | https://www.ncbi.nlm.nih.gov/pubmed/17986636

PF-915275 is a potent and selective 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) inhibitor (Ki = 2.3 nM) PF-915275 inhibits the conversion of prednisone to prednisolone in human hepatocytes in vitro (EC50 = 15 nM) and has antidiabetic activity in vivo. In first half 2007, Pfizer stopped developing PF 915275 for the treatment of type II diabetes mellitus.

Originator

Pfizer
420
Curator's Comment: # Pfizer

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase I
438
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
480 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17986636/
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PF-915275 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
18.8 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17986636/
0.3 mg 1 times / day steady-state, oral
dose: 0.3 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PF-915275 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
61 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17986636/
1 mg 1 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PF-915275 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
202 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17986636/
3 mg 1 times / day steady-state, oral
dose: 3 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PF-915275 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
956 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17986636/
15 mg 1 times / day steady-state, oral
dose: 15 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PF-915275 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
7392 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17986636/
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PF-915275 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
318 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17986636/
0.3 mg 1 times / day steady-state, oral
dose: 0.3 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PF-915275 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1047 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17986636/
1 mg 1 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PF-915275 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3366 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17986636/
3 mg 1 times / day steady-state, oral
dose: 3 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PF-915275 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
16344 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17986636/
15 mg 1 times / day steady-state, oral
dose: 15 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PF-915275 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
23.1 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17986636/
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PF-915275 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
30.4 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17986636/
0.3 mg 1 times / day steady-state, oral
dose: 0.3 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PF-915275 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
32.3 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17986636/
1 mg 1 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PF-915275 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
30.9 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17986636/
3 mg 1 times / day steady-state, oral
dose: 3 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PF-915275 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
31.8 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17986636/
15 mg 1 times / day steady-state, oral
dose: 15 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PF-915275 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
15 mg 1 times / day multiple, oral
Highest studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17986636
healthy
Health Status: healthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/17986636
Sources:
https://pubmed.ncbi.nlm.nih.gov/17986636
Sourcing

Sourcing

Vendor/AggregatorIDURL
1PlusChem LLC
1P004PLN
https://www.1pchem.com/search?query=1P004PLN
AChemBlock
P51733
http://www.achemblock.com/catalogsearch/result/?q=P51733
ApexBio Technology
B7346
https://www.apexbt.com/catalogsearch/result/?q=B7346
AstaTech
C16507
http://astatechinc.com/CPSResult.php?CRNO=C16507
BLD Pharm
BD630911
http://www.bldpharm.com/search/Search.html?keyword=BD630911
BOC Sciences
857290-04-1
http://www.bocsci.com/description.asp?cas=857290-04-1
Chem Scene
CS-5559
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-5559
eMolecules
29703147
https://orderbb.emolecules.com/search/#?query=29703147
eNovation Chemicals
D621094
https://www.enovationchem.com/Products.asp?SEARCHTEXT=D621094&searchbtn.x=0&searchbtn.y=0
Exclusive Chemistry
2428
http://www.exchemistry.com/chem-catalog/product-2428.html
mcule
MCULE-6049674977
https://mcule.com/MCULE-6049674977/
MedChem Express
HY-18056
https://www.medchemexpress.com/search.html?q=HY-18056&ft=&fa=&fp=
Molnova
M16219
https://www.molnova.com/en/serch-list.html?keywords=M16219
MolPort
MolPort-023-276-737
https://www.molport.com/shop/molecule-link/MolPort-023-276-737
Tocris
3291
https://www.tocris.com/search.php?Type=QuickSearch&Value=3291
Wonderchem
WD06TNH
http://www.wonder-chem.com/search.html?text=WD06TNH
PubMed

PubMed

TitleDatePubMed
Induction of 11β-HSD 1 and activation of distinct mineralocorticoid receptor- and glucocorticoid receptor-dependent gene networks in decidualizing human endometrial stromal cells.
2013-02
Cortisol and interferon tau regulation of endometrial function and conceptus development in female sheep.
2013-02
Will treating diabetes with 11β-HSD1 inhibitors affect the HPA axis?
2010-10
N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275.
2009-07-01
Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor.
2008-02
Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys.
2008-01
Patents

Patents

07462634
1
20070072914
1
20110159005
1
7462634
1
8871208
1
WO2006134467A1
1

Sample Use Guides

In Vivo Use Guide
Oral dose of PF-00915275 (0.3-15 mg)
Route of Administration: Oral
In Vitro Use Guide
PF-915275 is a selective and potent inhibitor of the human 11b-HSD1 (HEK293 EC50 = 5 nM) and showed good selectivity against 11b-HSD2 (1.5% inhibition at 10 uM).
Name Type Language
PF-915275
Common Name English
N-(6-AMINOPYRIDIN-2-YL)-4'-CYANOBIPHENYL-4-SULFONAMIDE
Preferred Name English
Code System Code Type Description
PUBCHEM
23725123
Created by admin on Mon Mar 31 21:24:42 GMT 2025 , Edited by admin on Mon Mar 31 21:24:42 GMT 2025
PRIMARY
FDA UNII
388927163B
Created by admin on Mon Mar 31 21:24:42 GMT 2025 , Edited by admin on Mon Mar 31 21:24:42 GMT 2025
PRIMARY
CAS
857290-04-1
Created by admin on Mon Mar 31 21:24:42 GMT 2025 , Edited by admin on Mon Mar 31 21:24:42 GMT 2025
PRIMARY
EPA CompTox
DTXSID00235037
Created by admin on Mon Mar 31 21:24:42 GMT 2025 , Edited by admin on Mon Mar 31 21:24:42 GMT 2025
PRIMARY
SUBSTANCE RECORD
Structure of PF-915275
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966